Praxis Precision Medicines, Inc. leverages its proprietary platforms, Cerebrum and Solidus, to discover and develop precision medicines for central nervous system disorders. The Cerebrum platform focuses on orally available small molecule therapies, while the Solidus platform is designed to develop antisense oligonucleotide (ASO) treatments. The company's clinical pipeline includes candidates targeting essential tremor, major depressive disorder, and rare pediatric epilepsies like SCN2A and SCN8A developmental and epileptic encephalopathies. By targeting shared biological circuits and genetic targets in the brain, Praxis aims to address both rare and prevalent neurological conditions.
